Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Scleroderma, Systemic, Digital Ulcer

In brief

This study is performed to consider the safety and healing ability of diosmin in patients with systemic sclerosis (scleroderma) and open sores on their fingers (digital ulcers). Two (2) out of three (3) participants will receive active product. The participants will have four (4) visits over eight (8) weeks. Physical exams and photos will be performed. A variety of questions will be asked describing level of pain and lifestyle changes.

Key facts

Study ID

NCT06256575

Run by

Primus Pharmaceuticals

People needed

45

Starts

2025-05-02

Expected to finish

2027-08-15

Last updated by the study team

2025-12-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of systemic sclerosis (scleroderma)
• At least one "active" digital ulcer
• Medication for systemic sclerosis unchanged for 30 days

You may not qualify if…

• Infection or gangrene in ulcer
• Citrus allergy
• Unstable heart, kidney, or liver disease
• Active infection of any type
• Current cancer treatment or uncured cancer
• Pregnancy or breast feeding

Where it is running

• University of Calgary — Calgary, Alberta, Canada (enrolling)
• Saint Joseph Health Care Centre — London, Ontario, Canada (enrolling)
• The Ottawa Hospital — Ottawa, Ontario, Canada (enrolling)
• Mount Sinai Health System — Toronto, Ontario, Canada (enrolling)
• Dalhousie University — Halifax, Nova Scotia, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.